Q3 2025 EPS Estimates for Humana Inc. (NYSE:HUM) Reduced by Analyst

Humana Inc. (NYSE:HUM) – Equities researchers at Zacks Research lowered their Q3 2025 earnings per share (EPS) estimates for Humana in a research report issued on Thursday, September 19th. Zacks Research analyst D. Chatterjee now expects that the insurance provider will post earnings per share of $4.83 for the quarter, down from their prior forecast of $4.84. The consensus estimate for Humana’s current full-year earnings is $16.00 per share. Zacks Research also issued estimates for Humana’s Q4 2025 earnings at $1.61 EPS.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.89 by $1.07. The firm had revenue of $29.54 billion for the quarter, compared to analyst estimates of $28.52 billion. Humana had a net margin of 1.53% and a return on equity of 16.12%. The company’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $8.94 earnings per share.

Several other research analysts also recently commented on the company. Piper Sandler initiated coverage on Humana in a research note on Wednesday, June 26th. They set an “overweight” rating and a $392.00 target price for the company. JPMorgan Chase & Co. increased their price objective on shares of Humana from $332.00 to $396.00 and gave the company a “neutral” rating in a research note on Wednesday, August 21st. Baird R W raised shares of Humana to a “hold” rating in a research note on Thursday, May 30th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Humana from $341.00 to $349.00 and gave the stock a “hold” rating in a report on Friday, August 2nd. Finally, Robert W. Baird assumed coverage on Humana in a report on Thursday, May 30th. They set a “neutral” rating and a $374.00 price objective on the stock. Thirteen equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, Humana presently has an average rating of “Hold” and an average price target of $398.70.

Humana Trading Down 0.5 %

Shares of HUM opened at $310.41 on Monday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.66 and a current ratio of 1.66. Humana has a 52-week low of $298.61 and a 52-week high of $530.54. The firm has a market cap of $37.40 billion, a price-to-earnings ratio of 19.33, a PEG ratio of 2.56 and a beta of 0.50. The business’s fifty day moving average is $357.71 and its 200-day moving average is $345.60.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be paid a $0.885 dividend. The ex-dividend date is Monday, September 30th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.14%. Humana’s payout ratio is presently 22.04%.

Hedge Funds Weigh In On Humana

Several institutional investors have recently modified their holdings of the business. Trexquant Investment LP bought a new stake in shares of Humana during the 4th quarter worth $2,099,000. Quest Partners LLC bought a new stake in Humana in the fourth quarter worth about $128,000. Cambridge Investment Research Advisors Inc. boosted its stake in Humana by 12.3% in the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 10,323 shares of the insurance provider’s stock valued at $4,726,000 after acquiring an additional 1,127 shares during the last quarter. SageView Advisory Group LLC bought a new position in shares of Humana during the 4th quarter valued at approximately $652,000. Finally, Advisory Services Network LLC grew its position in shares of Humana by 271.8% during the 4th quarter. Advisory Services Network LLC now owns 3,963 shares of the insurance provider’s stock valued at $1,815,000 after acquiring an additional 2,897 shares during the period. 92.38% of the stock is owned by institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.